11 results about "Plasma derived" patented technology

The present invention relates to a method and system for extracting proteins from precipitates, particularly recombinant and / or plasma derived proteins including immunoglobulins (Ig) such as immunoglobulin G (IgG).

A method of treating neurodegenerative diseases using hUCB plasma is presented herein. hUCB plasma attenuated the hyperactive response (Group III) and potentiated the normal response in Group I ALS patients, but did not alter that of the non-responders to PHA (Group II). The elevated activity of caspase 3 / 7 observed in the MNCs from ALS patients was significantly reduced by hUCB plasma treatment. The ability of hUCB plasma to modulate the mitogen cell response and reduce caspase activity suggest that the use of hUCB plasma alone, or with stem cells, may prove useful as a therapeutic in ALS patients. hUCB plasma was shown to increase therapeutic efficacy of MNCs as well as decrease apoptosis of MNCs. The cytokine profile of hUCB plasma supports its usefulness as a sole therapeutic as well as an additive to MNCs.

The present inventors examined the procoagulant activity of a multispecific antigen-binding molecule that functionally substitutes for FVIII using blood and plasma derived from FIX disorder patients. The result showed that multispecific antigen-binding molecules that functionally substitute for FVIII can be used not only as methods for preventing and / or treating bleeding in hemophilia A, acquired hemophilia A, von Willebrand disease, and hemophilia C, which are caused by FVIII dysfunction, but also as methods for preventing and / or treating bleeding in FIX disorders, because of their procoagulant activity. Furthermore, the effect of a FIX formulation could be enhanced by using it in combination with a multispecific antigen-binding molecule that functionally substitutes for FVIII, and it was shown that the combined use is promising as a combination therapy that shows stable hemostatic effects.

The present invention relates to a method and system for extracting proteins, in particular recombinant and / or plasma-derived proteins, including immunoglobulins (Ig), such as immunoglobulin G (IgG), from precipitate.

Provided herein are recombinant AAT proteins having high fucosylation levels and enhanced immunomodulatory biological activity as compared to a plasma derived AAT. Further provided are compositions including the same and methods for preparation thereof.

The present disclosure provides methods for improving diagnostic applications by using genome-wide patterns of plasma-derived fragmented cell-free DNA (cfDNA) derived by low-coverage whole genome sequencing. In particular, the present invention provides a new and effective method for subtyping non-small cell lung cancer in a subject as low-neuroendocrine non-small cell lung cancer or high-neuroendocrine non-small cell lung cancer.

The invention provides application of plasma-derived EVs after RIPC in preparation of a medicine for preventing and / or treating kidney injury, and belongs to the technical field of biological medicine. The RIPC plasma-derived EVs provided by the invention can be used for preparing medicines for preventing and / or treating kidney injury caused by unilateral ureteral obstruction combined with pelvic lipopolysaccharide (LPS) injection. In-vivo and in-vitro experiments prove that compared with normal plasma-derived EVs, the plasma-derived EVs after RIPC shows a remarkable and better protection effect on U-L model kidney injury and LPS-induced HK-2 cell injury. Therefore, by taking the EVs from the plasma after RIPC as the active ingredient, the application has a wide prospect in developing a novel treatment medicine for treating the obstruction complicated with the inflammatory renal injury.

The invention discloses an immunoaffinity separation method of hepatocyte-derived small extracellular vesicles in plasma and application of the immunoaffinity separation method, and relates to the technical field of biology. The separation method comprises the following steps: constructing a transgenic animal of which the hepatocyte specifically expresses the methionine-tRNA synthetase L274G mutant; the L-azido-n-leucine is administered into the transgenic animal, so that the transgenic animal expresses L-azido-n-leucine labeled protein; collecting and identifying L-azido-n-leucine labeled proteins in plasma-derived small extracellular vesicles, liver-derived small extracellular vesicles and liver tissues of the transgenic animal, carrying out cross analysis, and screening overlapped and highly expressed biomarkers; providing an antibody of the biomarker, and separating to obtain the hepatocyte-derived small extracellular vesicles in plasma through antigen-antibody specific binding. The effect of separating the hepatocyte-derived small extracellular vesicles by using the screened biomarker is remarkable, and a new thought and method are provided for disease diagnosis.

The application discloses application of exosome miRNA markers in evaluation of curative effect of immunotherapy combined with chemotherapy on small cell lung cancer patients. The exosome miRNA markers are a combination of miR-338-5p, miR-345-5p, miR-150-5p, miR-7706 and miR-328-3p. It is found for the first time that a combination of plasma exosome miRNA and TNM stage can be used as a marker to effectively predict a population benefiting from an immunotherapy combined with chemotherapy treatment scheme. Due to the unique structure of the exosome and the advantages of liquid biopsy technology, the exosome miR-338-5p, miR-345-5p, miR-150-5p, miR-7706, miR-328-3p and TNM stage combination of the application has high sensitivity and convenience as a population screening for benefiting from an immunotherapy combined with chemotherapy combined treatment scheme.

The present application relates to methods of treating infectious diseases with compositions containing plasma-derived immunoglobulin M (IgM). The compositions and methods of the invention prevent, inhibit, or reduce the toxic effects of proteins and toxins secreted by microorganisms. A method for neutralizing a microbial protein product in a subject includes administering to the subject a composition comprising plasma-derived IgM and, optionally, one or more excipients in the form of a pharmaceutical carrier, wherein the composition is administered in an amount effective to neutralize the microbial protein product.

The present application relates to the field of antibacterial technology, in particular to an AIE type cationic conjugated polymer and a preparation method, plasma activated hydrogel and application. The AIE type cationic conjugated polymer has the following structural formula. The present application combines the FADM photosensitizer with significant aggregation-induced emission characteristics and high ROS generation capacity with cold atmospheric pressure plasma technology, constructs a hydrogel material with synergistic antibacterial function of photodynamic and plasma derived reactive oxygen nitrogen species, and solves the problem that the half-life of RONS in PAW is extremely short, and the low viscosity leads to the difficulty of effective enrichment and maintenance of active ingredients in the infection site.